Literature DB >> 29115020

Glycosylphosphatidylinositol (GPI) anchored protein deficiency serves as a reliable reporter of Pig-a gene Mutation: Support from an in vitro assay based on L5178Y/Tk+/- cells and the CD90.2 antigen.

Jeffrey C Bemis1, Svetlana L Avlasevich1, Carson Labash1, Page McKinzie2, Javier Revollo2, Vasily N Dobrovolsky2, Stephen D Dertinger1.   

Abstract

Lack of cell surface glycosylphosphatidylinositol (GPI)-anchored protein(s) has been used as a reporter of Pig-a gene mutation in several model systems. As an extension of this work, our laboratory initiated development of an in vitro mutation assay based on the flow cytometric assessment of CD90.2 expression on the cell surface of the mouse lymphoma cell line L5178Y/Tk+/- . Cells were exposed to mutagenic and nonmutagenic compounds for 24 hr followed by washout and incubation for an additional 7 days. Following this mutant manifestation time, cells were labeled with fluorescent antibodies against CD90.2 and CD45 antigens. These reagents indicated the presence of GPI-anchored proteins and general cell surface membrane receptor integrity, respectively. Instrument set-up was aided by parallel processing of a GPI anchor-deficient subclone. Results show that the mutagens reproducibly caused increased frequencies of mutant phenotype cells, while the nonmutagens did not. Further modifications to the method, including application of a viability dye and an isotype control for instrument set-up, were investigated. As a means to verify that the GPI-anchored protein-negative phenotype reflects bona fide Pig-a gene mutation, sequencing was performed on 38 CD90.2-negative L5178Y/Tk+/- clones derived from cultures treated with ethyl methanesulfonate. All clones were found to have mutation(s) within the Pig-a gene. The continued investigation of L5178Y/Tk+/- cells, CD90.2 labeling, and flow cytometric analysis as the basis of an in vitro mutation assay is clearly supported by this work. These data also provide evidence of the reliability of using GPI anchor-deficiency as a valid reporter of Pig-a gene mutation. Environ. Mol. Mutagen. 59:18-29, 2018.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  L5178Y/Tk+/−; Pig-a; flow cytometry; fluorescent antibody labeling; gene mutation; mutagenesis; phenotype; phosphatidylinositol glycan complement class A gene; sequencing

Mesh:

Substances:

Year:  2017        PMID: 29115020      PMCID: PMC5771857          DOI: 10.1002/em.22154

Source DB:  PubMed          Journal:  Environ Mol Mutagen        ISSN: 0893-6692            Impact factor:   3.216


  33 in total

1.  Analysis of trifluorothymidine-resistant (TFTr) mutants of L5178Y/TK+/- mouse lymphoma cells.

Authors:  M M Moore; D Clive; J C Hozier; B E Howard; A G Batson; N T Turner; J Sawyer
Journal:  Mutat Res       Date:  1985-08       Impact factor: 2.433

2.  International Pig-a gene mutation assay trial: evaluation of transferability across 14 laboratories.

Authors:  Stephen D Dertinger; Souk Phonethepswath; Pamela Weller; John Nicolette; Joel Murray; Paul Sonders; Hans-Werner Vohr; Jing Shi; Ljubica Krsmanovic; Carol Gleason; Laura Custer; Andrew Henwood; Kevin Sweder; Leon F Stankowski; Daniel J Roberts; Amanda Giddings; Julia Kenny; Anthony M Lynch; Céline Defrain; Fabrice Nesslany; Bas-jan M van der Leede; Terry Van Doninck; Ann Schuermans; Kentaro Tanaka; Yoshie Hiwata; Osamu Tajima; Eleanor Wilde; Azeddine Elhajouji; William C Gunther; Catherine J Thiffeault; Thomas J Shutsky; Ronald D Fiedler; Takafumi Kimoto; Javed A Bhalli; Robert H Heflich; James T MacGregor
Journal:  Environ Mol Mutagen       Date:  2011-09-11       Impact factor: 3.216

3.  Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria.

Authors:  R A Brodsky; M S Vala; J P Barber; M E Medof; R J Jones
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

4.  Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapy.

Authors:  Stephen D Dertinger; Svetlana L Avlasevich; Dorothea K Torous; Jeffrey C Bemis; Souk Phonethepswath; Carson Labash; Kristine Carlson; Jared Mereness; John Cottom; James Palis; James T MacGregor
Journal:  Toxicol Sci       Date:  2014-05-05       Impact factor: 4.849

5.  A preliminary evaluation of the performance of the Muta Mouse (lacZ) and Big Blue (lacI) transgenic mouse mutation assays.

Authors:  V Morrison; J Ashby
Journal:  Mutagenesis       Date:  1994-07       Impact factor: 3.000

6.  Efficient monitoring of in vivo pig-a gene mutation and chromosomal damage: summary of 7 published studies and results from 11 new reference compounds.

Authors:  Stephen D Dertinger; Souk Phonethepswath; Svetlana L Avlasevich; Dorothea K Torous; Jared Mereness; Steven M Bryce; Jeffrey C Bemis; Sara Bell; Pamela Weller; James T Macgregor
Journal:  Toxicol Sci       Date:  2012-08-24       Impact factor: 4.849

7.  Spectrum of mutations induced by methyl and ethyl methanesulfonate at the hprt locus of normal and tag expressing Chinese hamster fibroblasts.

Authors:  A Klungland; K Laake; E Hoff; E Seeberg
Journal:  Carcinogenesis       Date:  1995-06       Impact factor: 4.944

8.  Detection of PIGO-deficient cells using proaerolysin: a valuable tool to investigate mechanisms of mutagenesis in the DT40 cell system.

Authors:  Jun Nakamura; Husamettin Gul; Xu Tian; Scott J Bultman; James A Swenberg
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

Review 9.  Biosynthesis and deficiencies of glycosylphosphatidylinositol.

Authors:  Taroh Kinoshita
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2014       Impact factor: 3.493

10.  Development of an in vitro PIG-A gene mutation assay in human cells.

Authors:  Benjamin J Rees; Matthew Tate; Anthony M Lynch; Catherine A Thornton; Gareth J Jenkins; Richard M Walmsley; George E Johnson
Journal:  Mutagenesis       Date:  2017-03-01       Impact factor: 2.954

View more
  2 in total

1.  Pig-a gene mutation assay study design: critical assessment of 3- versus 28-day repeat-dose treatment schedules.

Authors:  Azeddine Elhajouji; Tamsanqa Tafara Hove; Oliver O'Connell; Hansjoerg Martus; Stephen D Dertinger
Journal:  Mutagenesis       Date:  2020-09-12       Impact factor: 3.000

2.  Development of a novel PIG-A gene mutation assay based on a GPI-anchored fluorescent protein sensor.

Authors:  Xu Tian; Youjun Chen; Jun Nakamura
Journal:  Genes Environ       Date:  2019-12-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.